Dr. Shiva Shankar

Dr. Shiva Shankar
Endocrinologist, Hyderabad


  • 4 Hospitals
  • Languages :English, Hindi, Telugu


Managing Director, The Hyderabad Diabetes Centre chain


  • Endocrinology

  • Diabetology


  • Diabetes

  • Diabetes Type 1

  • Diabetes Type 2

  • Gestational Diabetes

  • Hypertension

    • Essential (primary) hypertension
    • Arterial Hypertension
    • High blood pressure



A post-graduate Diploma in Diabetology, Vuk Vrhovac University Clinic for Diabetes, Zagreb, Croatia

ACC in Diabetology, NIMS, Hyderabad

Received special training in diabetic foot care management, Kings College Hospital, London

Practice Information

Sunshine Hospitals, Hyderabad

Sunshine Hospitals, Hyderabad

Penderghast Road, Opp Parsi Dharamsala, Behind Paradise Hotel, Secunderabad, Hyderabad, Telangana - 500003


02:30 PM - 03:30 PM

Basavatarakam Indo American Cancer Institute And Research Centre, Hyderabad

Basavatarakam Indo American Cancer Institute And Research Centre, Hyderabad

Road No 14, Banjara Hills, Hyderabad, Telangana - 500034


04:00 PM - 05:00 PM

Hyderabad Diabetes Centre, Ameerpet

Hyderabad Diabetes Centre, Ameerpet

# 8-3-903, Nagarjuna Nagar, Ameerpet, Hyderabad, Telangana - 500073


10:00 AM - 01:30 PM

Hyderabad Diabetes Centre, Kukatpally

Hyderabad Diabetes Centre, Kukatpally

KPHB Colony, # MIG-241, Kukatpally, Hyderabad, Telangana - 500072


06:30 PM - 07:30 PM

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Shiva Shankar and his staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • Multicentre, Open Label, Non Randomised, on International, Observational, Safety & Effectiveness Study in Subjects Using Biphasic Insulin Aspart30 (Novomix30) for Treatment of Diabetes Mellsitus. (IMPROVE  STUDY).
  • A Cross Sectional Study (IDMPS). International Diabetes Management Practice Study HOE 901/9010-2005.
  • A Cross Sectional Study (IDMPS). International Diabetes Management Practice Study HOE 901/9010-2006.
  • An Open Label, Randomised, Comparative, Multicentric Clinical Trial to Evaluate the Safety and Efficacy of Pregabalin Sustained Release Formulation Compared to Pregabalin Conventional Release Formulation in Patients of Diabetic Peripheral Naturopathic Pain. 2008.
  • EDGE Study – A Multinational, Multicentre, Post-Authorisation, Prospective Observational Cohort Study to Assess the Profile of Vildagliptin and the Fixed-dose Combination of Vildagliptin/ Metformin Relative to Comparator Oral Anti-Diabetic Drugs in Patients with Type 2 Diabetes in a Real-World Setting. 2010-11.
  • A Randomised, Double Blind, Comparative, Prospective, Multicentre, Parallel Study to Assess Efficacy, Safety and Tolerability of Fixed Dose Combination of Repaglinide / Metformin IR Tablet When Compared with Metformin IR Tablet or Repaglinide Tablet in Adult Patients with Type 2 Diabetes Mellitus. 2011.
  • Member, Diabetes and Pregnancy Study Group in India (DIPSI)
  • Member, European Association for the Study of Diabetes (EASD)
  • Member, International Diabetes Federation (IDF)
  • Member, American Diabetes Association (ADA)
  • Member, Indian Thyroid Society (ITS).
  • Member, Indian Society of Bone and Mineral Research (ISBMR)
  • Member, Research Society for the Study of Diabetes in India. (RSSDI)
  • Member, Diabetic Foot Society of India (DFSI).